Quick Opdivo OK In Renal Cell Carcinoma; 5th Indication

Only a week after Bristol-Myers Squibb Co. revealed the FDA had accepted the company's supplemental biologics license application for its programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) as a treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy, regulators gave their blessing for the firm to market the drug for that use.